Our results demonstrate a ~3.1-fold increase in ITGB3 expression in PBMCs from RRMS patients compared to HCS, indicating that ITGB3 is not merely a bystander receptor but may play an active role in the immunopathology of MS. Here, ITGB3 is linked to myeloid sarcoma.